[Use of antiparkinsonian agents in Castilla-La Mancha. Estimate of prevalence of Parkinson disease].
BACKGROUND
Research concerning the prevalence of Parkinson disease (PD) are scarce; in addition with different methodologies. Therefore it is not possible to determine its true impact on public health in Castilla-La Mancha (CLM), Spain.


OBJECTIVE
Determine the prevalence of PD in CLM (332.0 and 332.1 of the ICD-9th revision) by the consumption of antiparkinsonian drugs.


METHODS
Calculating the daily defined doses (DDD) per 100,000 inhabitants (10(5)) for each of the prescribed antiparkinsonian drugs (Therapeutic Group, N04A), during 1994-1996 for each of the province of CLM. The data from prescriptions have been obtained from the Pharmaceutical Service of the Health and Consume Ministry of Spain, which cover 100% of the population.


RESULTS
The DDD determination's of L-Dopa per 10(5) inhabitants, a prevalence of 270.24 (IC 95%: 239.2-304.7) is estimated for the whole population. The consumption of L-Dopa by provinces and years (1994-1996) allows to know the distribution of PD in CLM.


CONCLUSIONS
The numbers obtained place to CLM in a middle-high prevalence; although methodological differences do not allow definitive conclusions.
Servicio de Asistencia Sanitaria, Consejería de Sanidad, Toledo, España.
J J
JJ
Criado-Alvarez
C
C
Romo-Barrientos
J
J
Martínez-Hernández
I
I
González-Solana
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology*; D015995:Prevalence; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology
D000978:Antiparkinson Agents
Consumo de antiparkinsonianos en Castilla-La Mancha. Estimación de la prevalencia de la enfermedad de Parkinson.